Amyloid in the Blood and Urine of patients with Alzheimer's Disease
Research type
Research Study
Full title
An Examination of the Relationship Between Amyloid in Blood and Urine, and Historical PET Scans or CSF, in Patients with Pre-Clinical Alzheimer’s Disease, MCI due to Alzheimer’s Disease, or Mild to Moderate Alzheimer’s Disease
IRAS ID
317119
Contact name
Jennifer Lynch
Contact email
Sponsor organisation
Pharmakure
Duration of Study in the UK
0 years, 5 months, 28 days
Research summary
Many patients, as part of previous clinical trials, in Alzheimer's Disease, will have had an historical PET scan, or lumber puncture, to measure the levels of a protein, found in the brain, called Amyloid, elevated levels of which, is involved in the development of Alzheimer’s Disease. PET scans and lumber punctures are not widely available, and are both invasive and expensive.
PharmaKure, the sponsors of this study, have developed a possible screening technique to evaluate Amyloid levels in blood and urine, which would be more practical to use, and could be used in all clinical settings, as well as being much cheaper. As a consequence, we are asking patients to allow us to take a blood sample, and provide a urine sample, so that we can see how this new technique relates to the previous PET scan, or lumbar puncture results.REC name
North of Scotland Research Ethics Committee 2
REC reference
22/NS/0106
Date of REC Opinion
9 Sep 2022
REC opinion
Further Information Favourable Opinion